These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 17913312)

  • 1. Access to vaccine technologies in developing countries: Brazil and India.
    Milstien JB; Gaulé P; Kaddar M
    Vaccine; 2007 Nov; 25(44):7610-9. PubMed ID: 17913312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What are today's orphaned vaccines?
    Wilde H
    Clin Infect Dis; 2001 Sep; 33(5):648-50. PubMed ID: 11486287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries.
    Jadhav S; Datla M; Kreeftenberg H; Hendriks J
    Vaccine; 2008 Mar; 26(13):1611-5. PubMed ID: 18294742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Casting off vaccine supply charity -- the pace quickens. CVI goal: quality vaccines for all children.
    CVI Forum; 1995 Oct; (10):9-13. PubMed ID: 12290725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of emerging manufacturers in access to innovative vaccines of public health importance.
    Milstien JB; Kaddar M
    Vaccine; 2010 Feb; 28(9):2115-21. PubMed ID: 20044054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines: Patent landscaping and perspectives of developing country vaccine manufacturers.
    Chandrasekharan S; Amin T; Kim J; Furrer E; Matterson AC; Schwalbe N; Nguyen A
    Vaccine; 2015 Nov; 33(46):6366-70. PubMed ID: 26368398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of agricultural technology to resource-poor farmers in Africa.
    Mignouna HD; Abang MM; Omanya G; Nang'ayo F; Bokanga M; Boadi R; Muchiri N; Terry E
    Ann N Y Acad Sci; 2008; 1136():369-76. PubMed ID: 17954683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing the effect of TRIPS on availability of priority vaccines.
    Milstien J; Kaddar M
    Bull World Health Organ; 2006 May; 84(5):360-5. PubMed ID: 16710544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza vaccine production for Brazil: a classic example of successful North-South bilateral technology transfer.
    Miyaki C; Meros M; Precioso AR; Raw I
    Vaccine; 2011 Jul; 29 Suppl 1():A12-5. PubMed ID: 21684420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vaccines: producers in countries of the Southern hemisphere].
    Bertrand JJ
    Med Trop (Mars); 2007 Aug; 67(4):347-50. PubMed ID: 17926792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brazil and India access pharma vaccine know-how.
    Neto RB; Jayaraman K
    Nat Biotechnol; 2009 Dec; 27(12):1063-4. PubMed ID: 20010560
    [No Abstract]   [Full Text] [Related]  

  • 13. [Improving global access to new vaccines: intellectual property, technology transfer, and regulatory pathways].
    Crager SE
    Rev Panam Salud Publica; 2015 Jan; 37(1):59-68. PubMed ID: 25791189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing Countries Vaccine Manufacturers Network (DCVMN): engaging to step up for vaccine discovery and access. Meeting report 2012.
    Pagliusi S; Makhoana M; Datla M; Leite L; Hendriks J; Gholami A; Huang W; Gao Y; Jadhav S; Harshavardhan GV; Wu Y; Suhardono M; Homma A
    Vaccine; 2013 Jun; 31(31):3111-5. PubMed ID: 23684836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The GO License: only part of the solution.
    Batson A; Milstien JB
    Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing Countries Vaccine Manufacturers Network: doing good by making high-quality vaccines affordable for all.
    Pagliusi S; Leite LC; Datla M; Makhoana M; Gao Y; Suhardono M; Jadhav S; Harshavardhan GV; Homma A
    Vaccine; 2013 Apr; 31 Suppl 2():B176-83. PubMed ID: 23598479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of globalization on vaccine development and availability.
    Milstien JB; Kaddar M; Kieny MP
    Health Aff (Millwood); 2006; 25(4):1061-9. PubMed ID: 16835187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Brazilian vaccine manufacturers' perspective and its current status.
    Homma A
    Biologicals; 2009 Jun; 37(3):173-6. PubMed ID: 19423359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRIPS post-2005 and access to new antiretroviral treatments in southern countries: issues and challenges.
    Orsi F; D'Almeida C; Hasenclever L; Camara M; Tigre P; Coriat B
    AIDS; 2007 Oct; 21(15):1997-2003. PubMed ID: 17885289
    [No Abstract]   [Full Text] [Related]  

  • 20. Needed: a new system of intellectual property rights.
    Thurow LC
    Harv Bus Rev; 1997; 75(5):94-103. PubMed ID: 10170334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.